Literature DB >> 1713513

Effect of single amino acid substitutions on the formation of the PlA and Bak alloantigenic epitopes.

A Goldberger1, M Kolodziej, M Poncz, J S Bennett, P J Newman.   

Abstract

The subunits that comprise the platelet-specific integrin alpha IIb beta 3 are polymorphic in nature, with several allelic forms present in the human gene pool. Minor changes in the secondary and tertiary structures of platelet membrane glycoproteins (GP) IIb and IIIa encoded by these alleles can result in an alloimmune reaction after transfusion or during pregnancy. To better understand the molecular structure of the PlA alloantigen system, located on GPIIIa, and the Bak alloantigen on GPIIb, we used a heterologous mammalian expression system to express these integrin subunits in their known polymorphic forms. An expression vector containing the PlA1 form of a GPIIIa cDNA, which encodes a leucine at amino acid 33 (Leu33), was modified to express the PlA2-associated form encoding a proline at amino acid 33 (Pro33). Similarly, a Baka GPIIb cDNA expressing an isoleucine at amino acid 843 (IIe843) was modified to express the Bakb form containing a serine at the same position (Ser843). Transfection of these vectors into COS cells resulted in the synthesis of GPIIb and GPIIIa molecules that were identical in size to those present in platelet lysates. Immunoprecipitation of the GPIIIa-transfected COS lysates with PlA)-specific alloantisera indicated that the Leu33 form was recognized only by anti-PIA1 sera while the Pro33 form was bound only by anti-PlA2 sera, showing that single amino acid polymorphisms are necessary and sufficient to direct the formation of the PlA1 and PlA2 alloepitopes. Similar experiments with Bak allele-specific expression vectors indicated that while the amino acid polymorphism (IIe843 in equilibrium Ser843) was necessary, posttranslational processing of pro-IIb was required for efficient exposure of both the Baka and Bakb alloepitopes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713513

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers.

Authors:  Cedric Ghevaert; Nina Herbert; Louise Hawkins; Nicola Grehan; Philip Cookson; Steve F Garner; Abigail Crisp-Hihn; Paul Lloyd-Evans; Amanda Evans; Kottekkattu Balan; Willem H Ouwehand; Kathryn L Armour; Mike R Clark; Lorna M Williamson
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

Review 2.  ABO Blood Group as a Model for Platelet Glycan Modification in Arterial Thrombosis.

Authors:  Ming Zhong; Hanrui Zhang; John P Reilly; Jason D Chrisitie; Mayumi Ishihara; Tadahiro Kumagai; Parastoo Azadi; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

3.  Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies.

Authors:  Nanyan Zhang; Sentot Santoso; Richard H Aster; Brian R Curtis; Peter J Newman
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

4.  Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia.

Authors:  K Maslanka; M Yassai; J Gorski
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1).

Authors:  Huiying Zhi; Maria Therese Ahlen; Aye Myat Myat Thinn; Hartmut Weiler; Brian R Curtis; Bjørn Skogen; Jieqing Zhu; Peter J Newman
Journal:  Blood Adv       Date:  2018-11-13

6.  Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia.

Authors:  Julie A Peterson; Stephanie M Balthazor; Brian R Curtis; Janice G McFarland; Richard H Aster
Journal:  Transfusion       Date:  2005-09       Impact factor: 3.157

7.  Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells.

Authors:  D A Wilcox; J C Olsen; L Ishizawa; M Griffith; G C White
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

8.  Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia.

Authors:  Juan Fang; Kairbaan Hodivala-Dilke; Bryon D Johnson; Lily M Du; Richard O Hynes; Gilbert C White; David A Wilcox
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

9.  An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system.

Authors:  R Wang; K Furihata; J G McFarland; K Friedman; R H Aster; P J Newman
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.

Authors:  Cedric Ghevaert; David A Wilcox; Juan Fang; Kathryn L Armour; Mike R Clark; Willem H Ouwehand; Lorna M Williamson
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.